October 19, 2016. In this testimony, we do not recommend this as the first drug approved for nocturia symptoms, unless there is a clinically meaningful benefit and sufficient safety profile for a clearly indicated population.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Letter to ACGME About Medical Residents’ Work Hours
October 13, 2016. We urge the ACGME to make patients’ lives a priority by keeping the first-year residents’ hours capped at 16 hours of continuous duty and to also apply the cap to all other residents.
Read More »NCHR Supports Increased User Fees for Generic Drugs
October 21, 2016. NCHR strongly supports increasing GDUFA and other user fees to improve FDA’s resources in order to enable the agency to fulfill its public health mission.
Read More »Public Health Advocates Support Tight FDA Restrictions on Pharmacy Compounded Drugs
October 11, 2016. NCHR strongly supports the draft guidance documents because they place tight restrictions on pharmacy compounding under sections 503A and 503B of the FD&C Act to prevent compounding drug products that are essentially copies of commercially available drug products and for those that are copies of approved drugs.
Read More »NCHR Position Regarding Anthem Decision that Exondys 51 is Experimental
October 7, 2016. We continue to strongly urge Sarepta to do the studies needed to support their claims that patients benefit from Exondys 51, and in the meanwhile Sarepta should ensure that patients in those studies receive the treatment for free.
Read More »